Download MendeleyHybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination.
Voss, W.N., Mallory, M.A., Byrne, P.O., Marchioni, J.M., Knudson, S.A., Powers, J.M., Leist, S.R., Dadonaite, B., Townsend, D.R., Kain, J., Huang, Y., Satterwhite, E., Castillo, I.N., Mattocks, M., Paresi, C., Munt, J.E., Scobey, T., Seeger, A., Premkumar, L., Bloom, J.D., Georgiou, G., McLellan, J.S., Baric, R.S., Lavinder, J.J., Ippolito, G.C.(2024) Cell Rep Med 5: 101668-101668
- PubMed: 39094579
- DOI: https://doi.org/10.1016/j.xcrm.2024.101668
- Primary Citation of Related Structures:
8VIF, 8VKE - PubMed Abstract:
We describe the molecular-level composition of polyclonal immunoglobulin G (IgG) anti-spike antibodies from ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, vaccination, or their combination ("hybrid immunity") at monoclonal resolution. Infection primarily triggers S2/N-terminal domain (NTD)-reactive antibodies, whereas vaccination mainly induces anti-receptor-binding domain (RBD) antibodies. This imprint persists after secondary exposures wherein >60% of ensuing hybrid immunity derives from the original IgG pool. Monoclonal constituents of the original IgG pool can increase breadth, affinity, and prevalence upon secondary exposures, as exemplified by the plasma antibody SC27. Following a breakthrough infection, vaccine-induced SC27 gained neutralization breadth and potency against SARS-CoV-2 variants and zoonotic viruses (half-maximal inhibitory concentration [IC 50 ] ∼0.1-1.75 nM) and increased its binding affinity to the protective RBD class 1/4 epitope (dissociation constant [K D ] < 5 pM). According to polyclonal escape analysis, SC27-like binding patterns are common in SARS-CoV-2 hybrid immunity. Our findings provide a detailed molecular definition of immunological imprinting and show that vaccination can produce class 1/4 (SC27-like) IgG antibodies circulating in the blood.
Organizational Affiliation:
Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
